Arcturus Therapeutics Holdings Inc

ARCT

Equity

ISIN null / Valor 48461643

NASDAQ (2026-03-23)

USD 6.87+3.62%

Arcturus Therapeutics Holdings Inc
UMushroom community rating:

3.33 12 votes No rating yet

NegativeNeutralPositive

About company

Arcturus Therapeutics Holdings Inc. is a clinical‑stage biotechnology company developing RNA‑based medicines and vaccines using proprietary lipid‑enabled delivery technology and a self‑amplifying mRNA platform designed to enable intracellular expression of therapeutic proteins and antigens. The company’s pipeline includes vaccine candidates and therapeutic programs targeting rare genetic and metabolic disorders, several of which have advanced into clinical studies, and it works with external partners and contract manufacturers to support development and supply. Headquartered in San Diego and publicly traded on Nasdaq, Arcturus focuses on progressing its clinical programs and demonstrating safety, efficacy and manufacturability as it seeks regulatory approval and potential commercialization.

Summarized from source with an LLMView SourceSector: Finance

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-46.7%1Y

-54.5%3Y

-83.9%5Y

Performance

106%1Y

86.6%3Y

92.6%5Y

Volatility

195 M

Market cap (USD)

584,956

Daily traded volume (Shares)

16.91 / 16.03

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

3.33

12 votes

Performance:

3.00

Innovation:

3.67

Society:

3.58

Nature:

3.42

Loic Lienard

Switzerland, 27 Oct 2025

Arcturus Therapeutics is a highly innovative biotech company focused on mRNA-based vaccines and treatments. Although still volatile and in early stages, it shows strong potential for long-term growth in the biotechnology and healthcare sectors.